Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05108558 · ClinicalTrials.gov registry record · Phase 4
Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders
A Phase 4 study of Peyronie's Disease, sponsored by Charitable Union for the Research and Education of Peyronie's Disease.
- Active
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05108558 is a Phase 4 study of Peyronie's Disease that is active but no longer recruiting, run by Charitable Union for the Research and Education of Peyronie's Disease. The registered enrollment target is 40 participants, below the 182-participant average among 5 other Peyronie's Disease trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05108558, a Phase 4 study of Peyronie's Disease, is active but no longer recruiting, sponsored by Charitable Union for the Research and Education of Peyronie's Disease.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Compare key clinical outcomes between controls and men treated with a novel CCH administration protocol among men previously unresponsive to CCH administration.
Conditions Studied
Interventions
- DEVICE RestoreX
- DRUG CCH administration
- DRUG Control - Crossover to CCH
Study Locations (1)
Utah
- The Male Fertility and Peyronie's Clinic - Orem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2028-09-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05108558
The ClinicalTrials.gov registry entry for NCT05108558 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 5 other Peyronie's Disease trials with a reported enrollment target (78% lower). The listed sponsor is Charitable Union for the Research and Education of Peyronie's Disease, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peyronie's Disease appearing as the primary indexed condition, and to 3 interventions - of which RestoreX is the first listed.
NCT05108558 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT05108558 about?
NCT05108558 is a clinical study titled "Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders". Compare key clinical outcomes between controls and men treated with a novel CCH administration protocol among men previously unresponsive to CCH administration.
What is the current status of trial NCT05108558?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2021-09-20. Estimated completion is 2028-09-20.
What conditions does trial NCT05108558 study?
This clinical trial studies the following conditions: Peyronie's Disease.
What interventions are being tested in trial NCT05108558?
The interventions under investigation include: RestoreX (DEVICE), CCH administration (DRUG), Control - Crossover to CCH (DRUG).
Who is sponsoring clinical trial NCT05108558?
This trial is sponsored by Charitable Union for the Research and Education of Peyronie's Disease, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05108558 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peyronie's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's
ACTIVE NOT RECRUITING · Phase 4
-
Study of AA4500 in the Treatment of Peyronie's Disease
COMPLETED · Phase 3
-
H-22411: BOTOX® for Peyronie's Disease
COMPLETED · Phase 2
-
Peyronie's Disease Treatment Protocol
COMPLETED · Phase 1
-
Study of AA4500 in the Treatment of Peyronie's Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.